SC
CTNM

Stempoint Capital’s Contineum Therapeutics CTNM Stock Holding History

Stempoint Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-265,833
Closed -$3.89M – 84
2024
Q4 		$3.89M Buy
+265,833
New +$4.21M 0.97% 35

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

Stempoint Capital's CTNM Position: Q1 2025 in Review

Stempoint Capital sold out of Contineum Therapeutics (CTNM) in Q1 2025, closing a stake of 265,833 shares — an estimated $3.89M sold.

Stempoint Capital first reported a position in CTNM in Q4 2024 and held it in 1 quarter. The position peaked at $3.89M in Q4 2024. 63 funds tracked by Wall St. Rank hold CTNM as of Q1 2025.

  • Stempoint Capital reported no remaining Contineum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stempoint Capital sold 265,833 Contineum Therapeutics shares in Q1 2025, an estimated $3.89M.
  • Stempoint Capital first reported a position in Contineum Therapeutics in Q4 2024 and held it in 1 quarter.
  • Stempoint Capital's Contineum Therapeutics position peaked at $3.89M in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.